Cite
MLA Citation
Sabrina Collins et al.. “357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A218. http://access.bl.uk/ark:/81055/vdc_100144717081.0x000007